Joshua A Roth1, Josh J Carlson. 1. University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, Washington 98195, USA. rothja@uw.edu
Abstract
UNLABELLED: Small observational studies have demonstrated an association between high ERCC1 expression level and poor prognosis in advanced NSCLC treated with platinum-based chemotherapy. This meta-analysis presents pooled estimates of association from 11 studies. High ERCC1 patients had lower response rates and higher risk of death relative to low ERCC1 patients. These results support the prognostic significance of ERCC1 expression level in advanced NSCLC. BACKGROUND: Observational studies have demonstrated an association between excision repair cross-complementation group 1 (ERCC1) expression level and health outcomes in patients with advanced non-small-cell lung cancer (NSCLC) treated with platinum-based regimens. This analysis presents pooled estimates of association from these studies to better elucidate the prognostic role of ERCC1 in advanced NSCLC. METHODS: A systematic literature search was conducted using the MEDLINE, EMBASE, and American Society of Clinical Oncology (ASCO) annual meeting databases from June 1995 to December 2010. Included studies were evaluated for clinical, methodological, and statistical heterogeneity. Pooled analyses were conducted using fixed and random effects models. RESULTS: In high ERCC1 expression versus low ERCC1 expression patients, pooled analysis results demonstrated a significantly lower response (risk ratio [RR], 0.80, 0.66-0.98) and significantly higher risk of death (hazard ratio [HR], 2.04, (1.48-2.80)), respectively. Subgroup analyses demonstrated significant heterogeneity in outcomes by ERCC1 measurement method (I(2): 90.7%, P = 0.001) and patient population ethnicity (I(2): 66%, P = 0.003). CONCLUSION: This study's findings support the hypothesis that ERCC1 expression is associated with response rate and overall survival (OS) in patients with advanced NSCLC treated with platinum-based chemotherapy. Heterogeneity in subgroup analyses demonstrates the need for standardized methods to classify ERCC1 expression level, studies evaluating the association between ERCC1 expression and OS in non-Asian populations, and studies evaluating interaction between ERCC1 and other known prognostic factors in advanced NSCLC. Copyright Â
UNLABELLED: Small observational studies have demonstrated an association between high ERCC1 expression level and poor prognosis in advanced NSCLC treated with platinum-based chemotherapy. This meta-analysis presents pooled estimates of association from 11 studies. High ERCC1patients had lower response rates and higher risk of death relative to low ERCC1patients. These results support the prognostic significance of ERCC1 expression level in advanced NSCLC. BACKGROUND: Observational studies have demonstrated an association between excision repair cross-complementation group 1 (ERCC1) expression level and health outcomes in patients with advanced non-small-cell lung cancer (NSCLC) treated with platinum-based regimens. This analysis presents pooled estimates of association from these studies to better elucidate the prognostic role of ERCC1 in advanced NSCLC. METHODS: A systematic literature search was conducted using the MEDLINE, EMBASE, and American Society of Clinical Oncology (ASCO) annual meeting databases from June 1995 to December 2010. Included studies were evaluated for clinical, methodological, and statistical heterogeneity. Pooled analyses were conducted using fixed and random effects models. RESULTS: In high ERCC1 expression versus low ERCC1 expression patients, pooled analysis results demonstrated a significantly lower response (risk ratio [RR], 0.80, 0.66-0.98) and significantly higher risk of death (hazard ratio [HR], 2.04, (1.48-2.80)), respectively. Subgroup analyses demonstrated significant heterogeneity in outcomes by ERCC1 measurement method (I(2): 90.7%, P = 0.001) and patient population ethnicity (I(2): 66%, P = 0.003). CONCLUSION: This study's findings support the hypothesis that ERCC1 expression is associated with response rate and overall survival (OS) in patients with advanced NSCLC treated with platinum-based chemotherapy. Heterogeneity in subgroup analyses demonstrates the need for standardized methods to classify ERCC1 expression level, studies evaluating the association between ERCC1 expression and OS in non-Asian populations, and studies evaluating interaction between ERCC1 and other known prognostic factors in advanced NSCLC. Copyright Â
Authors: Paul A Bunn; Rafal Dziadziuszko; Marileila Varella-Garcia; Wilbur A Franklin; Samir E Witta; Karen Kelly; Fred R Hirsch Journal: Clin Cancer Res Date: 2006-06-15 Impact factor: 12.531
Authors: J Bellmunt; L Paz-Ares; M Cuello; F L Cecere; S Albiol; V Guillem; E Gallardo; J Carles; P Mendez; J J de la Cruz; M Taron; R Rosell; J Baselga Journal: Ann Oncol Date: 2007-01-17 Impact factor: 32.976
Authors: Stefan Michiels; Pascal Piedbois; Sarah Burdett; Nathalie Syz; Lesley Stewart; Jean-Pierre Pignon Journal: Int J Technol Assess Health Care Date: 2005 Impact factor: 2.188
Authors: Ken A Olaussen; Ariane Dunant; Pierre Fouret; Elisabeth Brambilla; Fabrice André; Vincent Haddad; Estelle Taranchon; Martin Filipits; Robert Pirker; Helmut H Popper; Rolf Stahel; Laure Sabatier; Jean-Pierre Pignon; Thomas Tursz; Thierry Le Chevalier; Jean-Charles Soria Journal: N Engl J Med Date: 2006-09-07 Impact factor: 91.245
Authors: Reginald V N Lord; Jan Brabender; David Gandara; Vicente Alberola; Carlos Camps; Manuel Domine; Felip Cardenal; José M Sánchez; Paul H Gumerlock; Miquel Tarón; José J Sánchez; Kathleen D Danenberg; Peter V Danenberg; Rafael Rosell Journal: Clin Cancer Res Date: 2002-07 Impact factor: 12.531
Authors: Manuel Cobo; Dolores Isla; Bartomeu Massuti; Ana Montes; Jose Miguel Sanchez; Mariano Provencio; Nuria Viñolas; Luis Paz-Ares; Guillermo Lopez-Vivanco; Miguel Angel Muñoz; Enriqueta Felip; Vicente Alberola; Carlos Camps; Manuel Domine; Jose Javier Sanchez; Maria Sanchez-Ronco; Kathleen Danenberg; Miquel Taron; David Gandara; Rafael Rosell Journal: J Clin Oncol Date: 2007-07-01 Impact factor: 44.544
Authors: Matthias Villalobos; Piotr Czapiewski; Niels Reinmuth; Jürgen R Fischer; Stefan Andreas; Cornelius Kortsik; Monika Serke; Martin Wolf; Petra Neuser; Alexander Reuss; Philipp A Schnabel; Michael Thomas Journal: Med Oncol Date: 2018-06-15 Impact factor: 3.064
Authors: Alec E Vaezi; Gerold Bepler; Nikhil R Bhagwat; Agnes Malysa; Jennifer M Rubatt; Wei Chen; Brian L Hood; Thomas P Conrads; Lin Wang; Carolyn E Kemp; Laura J Niedernhofer Journal: Cancer Date: 2014-04-01 Impact factor: 6.860
Authors: Luc Friboulet; Ken André Olaussen; Jean-Pierre Pignon; Frances A Shepherd; Ming-Sound Tsao; Stephen Graziano; Robert Kratzke; Jean-Yves Douillard; Lesley Seymour; Robert Pirker; Martin Filipits; Fabrice André; Eric Solary; Florence Ponsonnailles; Angélique Robin; Annabelle Stoclin; Nicolas Dorvault; Frédéric Commo; Julien Adam; Elsa Vanhecke; Patrick Saulnier; Jürgen Thomale; Thierry Le Chevalier; Ariane Dunant; Vanessa Rousseau; Gwénaël Le Teuff; Elisabeth Brambilla; Jean-Charles Soria Journal: N Engl J Med Date: 2013-03-21 Impact factor: 91.245